2024 Spring Webinar Series for Pharmacists
April 8-9 and 16-19, 2024 | 12-1 p.m. ESTJoin us for the virtual Spring Webinar Series for Pharmacists and earn live CE credit. There will be five sessions over two weeks. You will need to register for each webinar that you wish to attend separately.
Registration for each session is complimentary for all. Advance registration is required for individual sessions. You will receive a registration confirmation email once you register. Registered individuals will receive a personalized access link from Zoom one day before and one hour before the webinar. Registration for each session will close one day before the webinar.
Register on the MCPHS CE Portal.
Each live webinar will be hosted on Zoom Webinar. Audience cameras and audio will be disabled. The presentations are pre-recorded to assure audio quality and connectivity, but the presenters will be present to pose engagement questions and answer inquiries throughout and after the session via the webinar Q&A function. Please contact continuing.education@mcphs.edu with any technical access questions.
The sessions will be available as on-demand modules for home study credit later in the month.
April 8-9 Live Webinars
12 - 1 p.m EST
This event is intended for pharmacists. It will provide an overview of Drug Safety and pharmacovigilance (PV).
The session will enhance pharmacist’s knowledge of this specialized field in the pharmaceutical/biotech industry and increase awareness of the topic, as well as highlight potential career pivots.
At the completion of this activity, the participant should be able to:
- Describe terminology used in the field of Drug Safety and Pharmacovigilance.
- Explain the main components of Drug Safety and Pharmacovigilance and their interconnection with other industry functions.
- Follow a case safety report through the standard reporting channels.
- Recognize the impact Drug Safety and Pharmacovigilance has on patient safety and public health.
Presenter
Chantal Kosmidis, PharmD, has extensive experience in the field of Pharmacovigilance, with over twenty years in clinical trial development and post-marketing safety/pharmacovigilance exposure across a variety of drug lifecycle phases. She received her PharmD from MCPHS.
ACPE UAN: 0026-0000-24-010-L05-P | Knowledge
Topic Designator: Patient Safety
Contact Hours: 1 (0.1 CEU)
12-1 p.m. EST
This event is intended for pharmacists.
The session will review the pathophysiology and guideline directed medical therapy for chronic heart failure. This includes reviewing the clinical presentation and classifications of chronic heart failure, the difference between HFrEF and HFpEF and a review of pharmacologic and nonpharmacologic treatment options. Additionally, the session will review latest guidelines for treatment management.
At the completion of this activity, the participant should be able to:
- Describe the pathogenesis clinical presentation and classifications of chronic heart failure
- Determine the difference between heart failure with reduced ejection fraction and heart failure with preserved ejection fraction
- Outline the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guideline for the Management of Heart Failure and the 2023 ACC Expert Consensus Decision Pathway on the Management of Heart Failure with Preserved Ejection Fraction
- Review the pharmacologic and nonpharmacologic treatment options for chronic heart failure
Presenter
Ashley Smith, PharmD, is a 2023-2024 MCPHS University/Atrius Health PGY-1 pharmacy resident. She earned her Doctor of Pharmacy at St. John Fisher University in Rochester, NY, where she was an active member in organizations such as the American College of Clinical Pharmacy and the American Society of Consultant Pharmacists. Ashley’s professional interests include chronic disease state management specifically in chronic heart failure, hypertension, type 2 diabetes and COPD/Asthma.
ACPE UAN: 0026-0000-24-009-L01-P | Knowledge
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1 (0.1 CEU)
April 16-19 Live Webinars
12 - 1 p.m EST
This event is intended for pharmacists.
The session will describe physiologic changes that occur to older adults as they age as well as summarize the 2023 update of the American Geriatrics Society Beers Criteria, helping pharmacists identify potentially inappropriate medications for older adults. Drug-drug interactions, drug-disease interactions, and renal dose adjustment for older adults will also be included throughout the presentation.
At the completion of this activity, the participant should be able to:
- Describe physiological changes in older adults that affect the pharmacokinetics and pharmacodynamics of medications.
- Identify medications that are considered inappropriate for older adults per the 2023 Update of the American Geriatrics Society Beers Criteria
- Choose an appropriate medication regimen for older adults by applying renal dose adjustments, and -minimizing the risk of adverse effects, drug-drug interactions, and drug-disease interactions.
Presenter
Emily Tsai, PharmD, completed her PharmD through Northeastern University and is currently a PGY-1 pharmacy residency at Mount Auburn Hospital, where the main population she works with are older patients. Her areas of interest include infusion center, oncology, and specialty pharmacy.
ACPE UAN: 0026-0000-24-008-L01-P | Knowledge
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1 (0.1 CEU)
12-1 p.m. EST
This event is intended for pharmacists.
The session will review the novel medications bempedoic acid and inclisiran for LDL reduction, as well as the evidence to support the use of these agents. A review of the treatment pathways and recommendations from recent guidelines that include these agents will be conducted, as well as a brief discussion of the place of therapy these agents have compared to the current standards of care.
At the completion of this activity, the participant should be able to:
- Explain the new non-statin lipid-lowering agents with the evidence on cardiovascular outcomes of non-statin lipid-lowering agents in recent clinical trials.
- Describe the current recommendations from the clinical practice guidelines in the management of atherosclerotic cardiovascular disease (ASCVD) risk.
- Choose an appropriate evidence-based treatment option for patients to optimize the risk management of ASCVD
Presenter
Nicole Camasura, PharmD, is a recent graduate of the University of Saint Joseph School of Pharmacy, where she was an active member with the American College of Clinical Pharmacy and Rho Chi Honor Society. She is currently a PGY-1 Pharmacy Resident at Mount Auburn Hospital in Cambridge, MA. Her current areas of interest include internal medicine, ambulatory care, and outpatient oncology.
ACPE UAN: 0026-0000-24-011-L01-P | Application
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1 (0.1 CEU)
12-1 p.m. EST
This event is intended for pharmacists.
At the completion of this activity, the participant should be able to:
- Understand the prevalence, risk factors, and pathophysiology of Type 2 Diabetes Mellitus (T2DM)
- Utilize evidence-based medication guideline-directed therapy to effectively manage T2DM and optimize patient glycemic outcomes
- Evaluate literature and design individualized therapy plans for patients with comorbid chronic diseases such as T2DM, atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD), and obesity.
- Discuss emerging trends and therapies in cardiometabolic risk management
Presenters
Stefanos Torkos, PharmD, BCACP, is an Endocrinology Clinical Pharmacist at Yale New Haven Health. He graduated from MCPHS with his PharmD in 2018.
Joseph Oliva, PharmD, BCACP, is a Clinical Pharmacist specializing in Ambulatory Care at Beth Israel Lahey Health. He graduated from MCPHS with his PharmD in 2018.
ACPE UAN: 0026-0000-24-012-L01-P | Application
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1 (0.1 CEU)
Accreditation
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participants will receive 1 contact hours (0.1 CEU) per session.
In order to receive credit, the participant must be present the entirety of each presentation and complete the post-test, and evaluation form for each session. Attendance will be verified. Upon completion of the evaluation, participant credit will be reported to CPE Monitor. Transcripts may be printed from the CPE Monitor.
Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.
Disclosures
Chantal Kosmidis, PharmD, holds a relevant financial relationship with the ineligible company Ipsen, where she is an employee. She was previously an employee of Sage Therapeutics and Biogen. The content developed does not endorse the product lines or solutions produced or offered by Ipsen, Sage Therapeutics, or Biogen.
Ashley Smith, PharmD, has no financial relationships with ineligible companies to disclose.
Emily Tsai, PharmD, has no financial relationships with ineligible companies to disclose.
Nicole Camasura, PharmD, has no financial relationships with ineligible companies to disclose.
Stefanos Torkos, PharmD, BCACP, has no financial relationships with ineligible companies to disclose.
Joseph Oliva, PharmD, BCACP, has no financial relationships with ineligible companies to disclose.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies.
No funding from industry provided for this event.